These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19364796)

  • 1. Thiazolidinedione use and the risk of fractures.
    Toulis KA; Goulis DG; Anastasilakis AD
    CMAJ; 2009 Apr; 180(8):841-2; author reply 842-3. PubMed ID: 19364796
    [No Abstract]   [Full Text] [Related]  

  • 2. Thiazolidinedione use and the risk of fractures.
    Reblin T
    CMAJ; 2009 Apr; 180(8):841. PubMed ID: 19364797
    [No Abstract]   [Full Text] [Related]  

  • 3. Thiazolidinediones: do harms outweigh benefits?
    Lipscombe LL
    CMAJ; 2009 Jan; 180(1):16-7. PubMed ID: 19073650
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
    Loke YK; Singh S; Furberg CD
    CMAJ; 2009 Jan; 180(1):32-9. PubMed ID: 19073651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.
    Douglas IJ; Evans SJ; Pocock S; Smeeth L
    PLoS Med; 2009 Sep; 6(9):e1000154. PubMed ID: 19787025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones and fractures: evidence from translating research into action for diabetes.
    Bilik D; McEwen LN; Brown MB; Pomeroy NE; Kim C; Asao K; Crosson JC; Duru OK; Ferrara A; Hsiao VC; Karter AJ; Lee PG; Marrero DG; Selby JV; Subramanian U; Herman WH
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4560-5. PubMed ID: 20631021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
    Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
    Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone and pioglitazone. Beware fractures.
    Dixit A; Pandey P
    BMJ; 2009 Sep; 339():b3957. PubMed ID: 19808816
    [No Abstract]   [Full Text] [Related]  

  • 9. Distal upper and lower limb fractures associated with thiazolidinedione use.
    Jones SG; Momin SR; Good MW; Shea TK; Patric K
    Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of rosiglitazone in the elderly diabetic patient.
    Viljoen A; Sinclair A
    Vasc Health Risk Manag; 2009; 5(1):389-95. PubMed ID: 19475776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
    Eckert S; Erdmann E; Lundershausen R; Forst T; Scherbaum WA; Schnell O; Standl E; Schumm-Draeger PM; Tschöpe D; Walter H; Weber M
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2650-3. PubMed ID: 18050033
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
    Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
    Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.
    Yaturu S; Bryant B; Jain SK
    Diabetes Care; 2007 Jun; 30(6):1574-6. PubMed ID: 17363747
    [No Abstract]   [Full Text] [Related]  

  • 14. Pioglitazone Therapy and Fractures: Systematic Review and Meta- Analysis.
    Pavlova V; Filipova E; Uzunova K; Kalinov K; Vekov T
    Endocr Metab Immune Disord Drug Targets; 2018; 18(5):502-507. PubMed ID: 29683100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.
    Schwartz AV; Chen H; Ambrosius WT; Sood A; Josse RG; Bonds DE; Schnall AM; Vittinghoff E; Bauer DC; Banerji MA; Cohen RM; Hamilton BP; Isakova T; Sellmeyer DE; Simmons DL; Shibli-Rahhal A; Williamson JD; Margolis KL
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4059-66. PubMed ID: 26305617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 2 diabetes, thiazolidinediones: bad to the bone?
    Watts NB; D'Alessio DA
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3276-8. PubMed ID: 16960122
    [No Abstract]   [Full Text] [Related]  

  • 17. The safety of rosiglitazone in the treatment of type 2 diabetes.
    Singh S; Loke YK
    Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of thiazolidinediones and fracture risk.
    Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
    Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 20. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.
    Beck GR; Khazai NB; Bouloux GF; Camalier CE; Lin Y; Garneys LM; Siqueira J; Peng L; Pasquel F; Umpierrez D; Smiley D; Umpierrez GE
    Transl Res; 2013 Mar; 161(3):145-55. PubMed ID: 23022285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.